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ABSTRACT 
Objective: To evaluate the hepatoprotective effect of Ambrex, a poly herbal formulation against methotrexate (MTX) induced hepatotoxicity in 
Swiss albino mice as well as in Chang liver cell lines.  
Methods: Ambrex was exposed to MTX intoxicated chang liver cells and cells were harvested for studying the gene expressions of Dihydrofolate 
reductase (DHFR), B-cell lymphoma 2 (BCL2) and Bcl-2-associated X protein (BAX). In in vivo study, Ambrex was administered orally for a period of 
7 days at two dose levels (250 and 500 mg/kg b. wt) and MTX (20 mg/kg b. wt, i. p) was injected one hour after the last test drug administration. 
Protective effect of Ambrex was evaluated by measuring aspartate transaminase (SGOT), alanine transaminase (SGPT), alkaline phosphatase (ALP), 
γ–glutamyl transferase (γGT) and total bilirubin. Its effect on superoxide dismutase (SOD), catalase (CAT), reduced glutathione (GSH) and lipid 
peroxide (LPO) was also determined.  
Results: Data revealed that Ambrex was able to restore the levels of antioxidants such as SOD, Catalase, and Glutathione to near normal and 
reduced the elevated plasma levels of SGOT, SGPT, ALP, γ–GT and total bilirubin. It also inhibited the formation of hepatic malondialdehyde induced 
by MTX. In vitro studies revealed that Ambrex protected MTX induced hepatotoxicity at the dose of 50 and 500ng/ml. Further, mRNA expression 
also illustrated that Ambrex inhibited the over expression of BAX and suppressed BCL2 and DHRF expressions.  
Conclusion: Results suggest that Ambrex has potent hepatoprotective effect which was evident from both in vivo and in vitro results. 
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INTRODUCTION 
Hepatic damages associated with chemotherapy are the most 
serious adverse effects with anti-cancer drugs. Methotrexate (MTX), 
is an anti folate and antimetabolite, widely used in the treatment of 
leukemia, lymphoma and several solid tumours [1]. MTX also used 
as a disease modifying antirheumatic drug (DMARD) and other 
autoimmune diseases including psoriasis.  
Chronic treatment with MTX reported to produce fatty liver and 
hepatic fibrosis and also portal hypertension in some cases. Further, 
MTX produces hepatic and renal oxidative stress on chronic 
exposure [2, 3]. Administration of MTX for a period of 6 weeks 
shown to increase Thiobarbituric acid reactive substance (TBARS) 
content and decrease in the activities of superoxide dismutase, 
catalase, and glutathione reductase in rats [4].  
Plant based drugs are well known for their protective effects against 
oxidative stress. Antioxidants as an adjuvant therapy in cancer 
treatment are shown to retard or slow down the oxidative stress in 
clinical set up. In particular, bioactive compounds such as total 
phenols, flavonoid and tannins from plants sources are extensively 
studied and reported for their benefits in various livers disorders 
and associated oxidative stress [5, 6].  
Ambrex, a polyherbal formulation, contains the fine blend of 
herbs such as Withania somnifera (100 mg,) amber (37.50 mg), 
Pistacia lentiscus (25 mg), Orchis mascula (25 mg) and Cycas 
circinalis (62.5 mg). Earlier studies have demonstrated the anti-
hyperlipidemic [7], anti-microbial [8] and its effect on oxidative 
stress in hyper lipidemic rats [9].  
Recently, we have also demonstrated the protective effect of 
ambrex against D-galactosmine induced hepatic damage (under 
review). The present study was undertaken to investigate 
whether Ambrex has the potency to counteract the oxidative 
stress and liver necrosis triggered by MTX in in vitro and in vivo 
(mice) models. 
MATERIALS AND METHODS 
Drugs and chemicals 
All cell culture solutions and supplements were purchased from Life 
Technologies Inc., USA. Dulbecco’s Modified Eagle Medium (DMEM) 
was obtained from GIBCO, USA. MTX was obtained from Sigma 
Aldrich, USA. LIV–52 was purchased from Himalayas, India. 
Biochemical kits were obtained from Merck, India. Ambrex was 
procured from Care and Cure Herbs Ltd., India. All other chemicals 
and reagents were of analytical grade obtained from Himedia, India 
and Sisco Research Laboratories Pvt. Ltd., India. 
In vitro study in chang liver cells 
Cell culture and maintenance  
Chang liver cells, a human hepatoma cells were obtained from the 
National Centre for Cell Science (NCCS), Pune, India. Cells were 
maintained in DMEM supplemented with 10% Fetal Bovine Serum 
(FBS), 100units/ml penicillin and 100μg/ml streptomycin. Cells 
were cultured in 75 cm2
Cell proliferation assay or MTT assay 
 culture flask and incubated at the 
humidified atmosphere with 5% CO2 at 37 °C. 
Cell respiration as an indicator of cell viability and proliferation was 
determined using a mitochondrial dependent reduction of 3-(4, 5-
dimethylthiazol-2-yl)-2,5-Diphenyl tetrazolium bromide (MTT) to 
formazan. Pre-confluent Chang liver cells were seeded in 96-well 
plates at a density of 8,000cells/200μl/well. Cells were treated with 
different concentrations of methotrexate hydrochloride (1, 3, 10, 30, 
100 and 300 mM) or the test drug (ranging from 1X10-3-1X106 ng) 
after 24h following plating and incubated at 37 °C for one day. At 
20h following drug exposure, the cells were incubated at 37 °C with 
0.5 mg/ml MTT for 4h. At the end of the experiment, the medium 
was removed, and the insoluble formazan product was dissolved in 
DMSO (200μl) and kept at least 15 minutes in dark. The intensity of 
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purple blue colour developed was measured at 570 and 630 nm 
using Thermo scientific multi scan spectrophotometer, USA.  
Percentage growth inhibitory rate of the test drug was calculated 
using the formula 
% Growth inhibitory rate = ([Control OD–Test OD]/Control OD) * 100 
MTX induced hepatotoxicity in chang liver cells 
Chang liver cells were seeded in 6 well plates at a density of 
1x105
Reverse transcriptase-Polymerase chain reaction (RT-PCR) 
cells/well and allowed to grow for a period of 24h. Ambrex 
was administered at a concentration of 5, 50 and 500 ng/ml. One 
hour following test drug exposure, methotrexate dissolved in DMSO 
(100 mM) was added to each well except the control and incubated 
for a period of 24 h. Cells were then trypsinised for measuring gene 
expressions of DHFR, BAX and BCL2. 
Total RNA was extracted using TRIzol Reagent (Sigma, USA). After 
homogenizing the cells with TRIzol reagent, the tubes were 
incubated for 10 min and centrifuged at 1000 rpm for 5 min. 200µl 
of chloroform were added to the supernatant, allowed to incubate 
for 5 min at room temperature and centrifuged at 12000rcf for 20 
min. Then 500µl of isopropyl alcohol was added to the supernatant 
to precipitate the total RNA and centrifuged at 12000rcf for 15 min 
following the incubation period of 10 min.  
The supernatant was decanted carefully; the pellet was washed thrice 
with 75% ethanol, centrifuged at 12000 rcf for 15 min. The pellet was 
air dried and re-suspended in 20µl of RNase free water and stored in-
80 °C until use. RT-PCR was carried out using PCR master cycler 
gradient (Eppendorf, Germany) and semi-quantified using Bio1D 
software in gel documentation (Vilber Loumart, France).  
Primers sequence used were as follows, GAPDH: sense, 5’-CGA CAG 
TCA GCC GCA TCT T-3’; antisense, 5’-CCA ATA CGA CCA AAT CCG 
TTG-3’, DHFR: sense, 5’-CTG TCA TGG TTG GTT CGC-3’; antisense 5’-
AAG CTT TTG GTA TTT CCA-3’, BAX: sense, 5’-TTT TGC TTC AGG 
GTT TCA TC-3’; antisense, 5’-GAC ACT CGC TCA GCT TCT TG-3’, and 
BCL2: sense, 5’-ATG TGT GTG GAG AGC GTC AAC C-3’; antisense, 5’-
TGA GCA GAG TCT TCA GAG ACA GCC-3’. 
In vivo study in mice model 
Animal husbandry 
Young healthy adult male swiss albino mice (18-22 g) were obtained 
from central animal facility, Sri Ramachandra University, Chennai, 
India. Animals were housed in colony cages (6 animals/cage) and 
were kept under laboratory standard conditions with 22±3 °C 
temperature, 12-h light/12-h dark cycle and 30-70% relative 
humidity. They were provided with rodent feed (M/s. Provimi 
Animal Nutrition India Pvt. Ltd, India) and purified water ad libitum. 
Animals were acclimatized at least for 7 days to the laboratory 
conditions prior to initiation of the experiment. Guidelines of “Guide 
for the Care and Use of Laboratory Animals” (Institute of Laboratory 
Animal Resources, National Academic Press 1996; NIH publication 
number #85-23, revised 1996) were strictly followed throughout 
the study. Institutional Animal Ethical Committee (IAEC), Sri 
Ramachandra University, Chennai, India approved the study 
protocol (IAEC No: IAEC/XXXIII/SRU/268/2013).  
Experimental study design 
The experimental animals were divided into five groups with six 
animals in each. Group I served as normal control, which received 
vehicle. Group II received the single dose of MTX (20 mg/kg i. p.) and 
vehicle. Group III served as reference control received LIV-52 (100 
mg/kg p. o.)+MTX (20 mg/kg i. p.). Group IV & V received Ambrex at 
250 and 500 mg/kg p. o.+MTX (20 mg/kg i. p.). Animals were pre-
treated with vehicle or the respective drug for a period of 7 days. 
MTX was injected intraperitoneally on day 7, one hour after test 
drug administration. 24 h following MTX injection, blood was 
collected from 3-4h fasted mice through retro orbital puncture and 
then sacrificed. Liver tissue was excised out, cleared of blood in ice 
cold saline and stored in -80 °C.  
Biochemical assays 
Plasma biochemical parameters 
SGOT, SGPT, ALP, γ-GT and total bilirubin were measured using 
commercial diagnostic kits (Merck, India) in semi-automatic 
biochemical analyser (Biosystem, India) 
Superoxide dismutase (SOD) activity 
SOD activity was performed by mixing 0.05 ml of 10% tissue 
homogenated with 0.3 ml of sodium pyrophosphate buffer 
(0.025M, pH 8.3), 0.025 ml of phenasonium metho sulphate 
(186µM) and 0.075 ml of nitroblue tetrazolium (300µM in buffer 
of pH 8.3). The reaction was started by addition of 0.075 ml of 
NADH (780µM in buffer of pH 8.3). After incubation at 30 °C for 
90 seconds, the reaction was stopped by addition of 0.25 ml 
glacial acetic acid.  
Then the reaction mixture was stirred vigorously and shaken 
with 2.0 ml of n-Butanol. The mixture was allowed to stand for 
10 minutes and centrifuged. 1.5 ml of n-butanol alone was 
served as blank. The colour intensity of the chromogen was read 
at 560 nm using Thermo Scientific multi scan 
spectrophotometer, USA [10].  
Lipid peroxide (LPO) content 
The method involved heating of 0.2 ml of 10% tissue homogenate 
with 0.8 ml saline, 0.5 ml of butylated hydroxyl toluene and 3.5 ml 
thio barburic acid (TBA) reagent for 1½h in a boiling water bath. 
After cooling, the solution was centrifuged at 3500rpm for 10 min 
and the precipitate obtained was removed. The absorbance of the 
supernatant was determined at 532 nm using Thermo Scientific 
multi scan spectrophotometer, USA against a blank that contained all 
the reagents except the sample [11]. 
Reduced glutathione (GSH) content 
Glutathione content was estimated according to the method of 
Moren et al. [12]. 0.25 ml of 10% homogenate was added to equal 
volume of ice cold 5% trichloro acetic acid. The precipitate was 
removed by centrifugation at 3500rpm for 10 minutes. To 1 ml of 
the supernatant, 0.25 ml of 0.2M phosphate buffer, pH 8.0 and 0.5 ml 
of 5,5'-dithiobis-(2-nitrobenzoic acid (0.6 mM in 0.2M phosphate 
buffer, pH 8.0) were added and mixed well. The absorbance was 
read at 412 nm using Thermo Scientific multiskan 
spectrophotometer, USA.  
Catalase (CAT) activity 
CAT assay was performed as described by Sinha, [13] with slight 
modification. The reaction mixture contained H2O2
Histopathology  
 (2 mM) and 0.2 
ml of the homogenate in a final volume of 1 ml phosphate buffer (10 
mM, pH 7.4). It was incubated at 37 °C for 5 min and then 
Dichromate Acetic Acid reagent (5% Potassium dichromate in water, 
Glacial Acetic Acid mixed in 1:3 ratio) was added and absorbance 
was taken at 570 nm using Thermo Scientific multiskan 
spectrophotometer, USA. 2 ml Dichromate Acetic acid reagent acts as 
blank whereas the reaction mixture without homogenate acts as 
control. 
The experimental animals were sacrificed; liver was excised out and 
fixed in 10% neutral buffered formalin solution for 48 hours. The 
tissue was then trimmed, dehydrated in graded alcohol and 
embedded in paraffin. Paraffin sections of 3-4 micron thickness were 
obtained, mounted on glass slides, counter-stained with 
Haematoxylin and Eosin (H&E) and examined under light 
microscope (Motic DMB1–2MP, China). 
Statistical analysis 
Data were expressed in mean±standard error of the mean (SEM). 
Mean difference between the groups was analysed by one-way 
analysis of variance (ANOVA) followed by Tukey’s multiple 
comparison test as posthoc using graph Pad Version 5. p≤0.05 is 
considered to be the statistical significance. 
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RESULTS  
In vitro study in chang liver cells 
Cytotoxicity assay  
Cytotoxicity was assessed for MTX and Ambrex at the concentration 
range of 1–300 mM/ml and 1X10-3-1X106 ng/ml, respectively 
following 24h incubation. It was observed that MTX and ambrex 
showed an IC50
 
 value of 101.12 mM/ml and 44.73 ng/ml, 
respectively when exposed in chang liver cells for a period of 24h. 
Based on the above results, the effect of ambrex against MTX 
induced hepatotoxicity was carried out at three different 
concentrations (5, 50 and 500ng/ml) and MTX concentration was 




















































































Fig. 1: Cytotoxicity potential of Ambrex (A) and MTX (B) in chang liver cells using MTT assay 
 
RT–PCR analysis 
A significant up-regulation of BAX (p<0.01) and down-regulation of 
BCL2 and DHFR (p<0.01) mRNA expressions were observed in MTX 
induced positive control cells when compared to normal chang liver 
cells. Treatment with Ambrex at 50 and 500 ng/ml significantly 
decreased the BAX expression and increased BCL2 and DHFR 
expressions in MTX intoxicated chang liver cells (fig. 2). 
In vivo study in mice model  
Biochemistry  
MTX induced positive control mice showed a significant increase in 
SGOT (p<0.01), SGPT (p<0.01), ALP (p<0.01), γ-GT (p<0.01), total 
bilirubin (p<0.01) and TBARS (p<0.01) and significant decrease in 
GSH (p<0.01) content, SOD (p<0.01) and catalase (p<0.01) activity 
when compared to normal mice. Administration of Ambrex at 250 
and 500 mg/kg significantly decreased SGOT (p<0.01), SGPT 
(p<0.01), ALP (p<0.01), γ-GT (p<0.01), total bilirubin (p<0.01 at high 
dose) and TBARS (p<0.01) content and increased GSH (p<0.01 at 
high dose) content, SOD (p<0.01 at high dose) and catalase (p<0.01 
at high dose) activity in comparison to MTX intoxicated mice and the 
values were found to be comparable with that of the reference drug, 
LIV52 (fig. 3). 
Histopathology  
Histological profile of the normal control group revealed normal 
histology of liver with central vein, hepatocytes and portal triads. 
MTX induced group revealed marked degree of centrilobular 
necrosis along with polymorphonuclear cells infiltration, severe 
vacuolations in the hepatocytes and sinusoidal congestion. Pre-
treatment with LIV-52 reduced MTX induced microscopic changs 
and showed marked beneficial effects in the liver architecture. 
Ambrex treatment at the low dose showed moderate degree of 
necrosis, mild degree of vacuolations in the hepatocytes with 
minimal sinusoidal congestion. Ambrex administration at high dose 
revealed regeneration of hepatocytes to normal architecture, absence 
of sinusoidal congestion and vacuolations in the hepatocytes. On the 
basis of the above observation, it is concluded that pre-treatment with 
Ambrex at high dose (500 mg/kg b. wt. p. o) have hepatoprotective 
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Fig. 2: Effect of ambrex on MTX induced hepatotoxicity in chang liver cell line. (A). Representative bar graphs of mRNA expression. Lane I: 
Normal control; Lane II: Positive control; Lane III: Low dose; Lane IV: Mid dose; Lane V: High dose. (B-D) Values were expressed in 
mean±SEM; Statistical analysis was performed using one way anova followed by tukey’s multiple comparison tests in Graph pad prism 
5.0. ##represents p<0.01 vs Normal control; **
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Fig. 3: Effect on Ambrex on liver and oxidative stress markers level in MTX intoxicated mice. Graph represents (A) SGOT, (B) SGPT, (C) 
ALP, (D) γ-GT, (E) total bilirubin, (F) TBARS, (G) SOD, (H) GSH and (I) Catalase activity. Values are expressed in mean±SEM; n=6/group; 
mean difference between the groups were analysed by one way ANOVA followed by Tukey’s multiple comparsion test as posthoc; ##
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Fig. 4: Representative photograph showing the effect of Ambrex on MTX induced mice liver-H & E stain X400 magnification. (A) Normal 




MTX is widely used as a cytotoxic chemotherapeutic agent in the 
treatment of malignancies but its efficacy is limited due to its severe 
side effects leading to various conditions such as liver cirrhosis, 
fibrosis of the liver, hypertrophy of the hepatocytes, hepatitis, 
hepato-cellular necrosis and death [14-16]. Numerous studies have 
used MTX as an animal model to study the drugs for its 
hepatoprotective activity [4, 17]. The present study showed that 
Ambrex exerts potent hepatoprotective activity in MTX induced liver 
toxicity in mice by regulating the oxidative stress markers. 
It is well known that MTX induces oxidative stress by increasing 
lipid peroxidation in different tissues [18]. The reactive oxygen 
species (ROS) thus formed from oxidative stress further leads to the 
cellular damage by peroxidation of membrane lipids, protein cross-
linking and DNA breakdown [19-21] showed that hydrogen peroxide 
is implicated in MTX induced lipid peroxidation. Catalase and SOD, 
which acts as potent antioxidants plays an important role in the 
detoxicification of hydrogen peroxide and lipid peroxidation [22, 
23]. In the present study, the decreased TBARS content and 
increased GSH content, catalase and SOD activity in Ambrex 
administration showed its potent anti-oxidant status in ameliorating 
the MTX induced liver damage.  
Increased liver markers such as SGOT, SGPT and ALP activity was 
observed in MTX intoxicated rabbit which shows the increased 
permeability, damage or necrosis of hepatocytes [24, 25] showed 
that MTX induces apoptosis through oxidative stress pathway. The 
decreased activities of liver markers such as SGOT, SGPT, ALP, γ-GT 
and bilirubin and altering apoptotic markers such as BAX and BCL2 
observed in the present study implicates the effectiveness of Ambrex 
against MTX intoxicated liver damage. The histopathological 
evidences also showed that Ambrex protects hepatocytes against 
MTX induced damage. 
CONCLUSION 
In conclusion, Ambrex showed hepatoprotectivity against MTX 
induced liver damage by enhancing the anti-oxidants. The present 
study demonstrated that Ambrex acts as hepatoprotective agent 
which was evident from both in vitro and in vivo studies. This 
preventive action of Ambrex might be attributed to the synergistic 




MTX: Methotrexate; SGOT: Aspartate transaminase; SGPT: Alanine 
transaminase; ALP: Alkaline phosphatase; γ-GT: γ–glutamyl 
transferase; SOD: Superoxide dismutase; CAT: Catalase; GSH: 
Reduced glutathione; LPO: Lipid peroxide; ROS: Reactive oxygen 
species; MEM: Minimal Essential Medium; TBA: Thiobarburic acid; 
BHT: Butylated hydroxyl toluene; MTT: 3-(4, 5-dimethylthiazol-2-
yl)-2,5-Diphenyl tetrazolium bromide; RT-PCR: Reverse 
transcriptase-Polymerase Chain Reaction; DHFR: Dihydrofolate 
reductase; BCL2: B-cell lymphoma 2; BAX: Bcl-2-associated X 
protein. 
CONFLICT OF INTERESTS 
The authors declare no conflict of interest 
REFERENCES  
1. Tobias H, Auerbach R. Hepatotoxicity of long term 
methotrexate therapy for psoriasis. Arch Intern Med 
1973;132:391–6. 
2. Kumar O, Sugendran K, Vijayaraghavan R. Oxidative stress 
associated hepatic and renal toxicity induced by ricin in mice. 
Toxicon 2003;1:333–8. 
3. Tafazoli S, Spehar DD, O’Brien PJ. Oxidative stress mediated 
idiosyncratic drug toxicity. Drug Metab Rev 2005;37:311–25.  
4. Coleshowers CL, Oguntibeju OO, Ukpong M, Truter EJ. Effects of 
methotrexate on antioxidant enzyme status in a rodent model. 
Med Technol 2010;24:5-9. 
5. Singh R, Verma PK, Singh G. Total phenolic, flavonoids and 
tannin contents in different extracts of Artemisia absinthium. J 
Intercult Ethnopharmacol 2012;1:101-4. 
6. Mohammed HA, Alshalmani SK, Abdellatif AG. Antioxidant and 
quantitative estimation of phenolic and flavonoids of three 
halophytic plants growing in libya. J Pharmacogn Phytochem 
2013;2:89-94. 
7. Devi AJ, Rajkumar J. Antihyperlipidemic effect of ambrex, a 
polyherbal formulation against experimentally induced 
hypercholesterolemia in rats. Afr J Pharm Pharmacol 
2013;7:1737-43. 
8. Ravindran R, Devi AJ, Krithika, Lavanya, Rajkumar J. 
Phytochemical screening, GC-MS analysis and antimicrobial 
evaluation of ambrex (a herbal formulation). Int J Pharm Res 
2014;2:31-5. 
9. Devi AJ, Ravindran R, Sankar M, Rajkumar J. Effect of Ambrex (a 
herbal formulation) on oxidative stress in hyperlipidemic rats 
and differentiation of 3T3-L1 preadipocytes. Pharmacogn Mag 
2014;10:165-71.  
10. Kakkar P, Das B, Viswanathan PN. A modified 
spectrophotometric assay of superoxide dismutase. 
Indian J Biochem Biophys 1984;21:130-2. 
11. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal 
tissues by thiobarbituric acid reaction. Ann Biochem 
1979;95:351-8. 
12. Moren MS, Desplerra JW, Mannervik B. Levels of glutathione, 
glutathione reductase and glutathione S-transferase activities 
in rat lung and liver. Biochim Biophys Acta 1979;585:67-78. 
13. Sinha AK. Calorimetric assay of catalase. Anal Biochem 
1972;47:389-94. 
14. Uzar E, Sahin O, Koyuncuoglu HR, Uz E, Bas O, Kilbas S, et al. 
The activity of adenosine deaminase and the level of nitric 
oxide in spinal cord of methotrexate administered rats. Toxicol 
2006;218:125-33. 
Anila et al. 
Int J Pharm Pharm Sci, Vol 7, Issue 8, 164-170 
170 
15. Cetinkaya A, Bulbuloglu E, Kurutas E, Kantarceken B. N-
acetylcysteine ameliorates methotrexate–induced oxidative 
liver damage in rats. Med Sci Monit 2006;12:274-8. 
16. Mahoney DH Jr, Shuster JJ, Nitschke R, Lauer SJ, Steuber CP, 
Winick N, et al. Acute neurotoxicity in children with B-
precursor acute lymphoid leukaemia: an association with 
intermediate-dose intravenous methotrexate and intrathecal 
triple therapy. J Clin Oncol 1998;16:1712-22. 
17. Issabeagloo E, Ahmadpoor F, Kermanizadeh P, Taghizadiyeh M. 
Hepatoprotective actions of melatonin against methotrexate 
induced hepatic injury in animal model. Res J Biol Sci 2011;6:381-5. 
18. Jahovic N, Cevik H, Sehirli AO, Yegen BC, Goksel S. Melatonin 
prevents methotrexate–induced hepatorenal oxidative injury in 
rats. J Pineal Res 2003;34:282-7. 
19. Babiak RM, Campello AP, Carieri EG, Oliveira MB. Methotrexate: 
pentose cycle and oxidative stress. Cell Biochem Funct 
1998;16:283-93. 
20. Cetiner M, Sener G, Sehirli AO, Eksioglu-Demiralp E, Ercan F, 
Sirvanci S, et al. Taurine protects against methotrexate-induced 
toxicity and inhibits leukocyte death. Toxicol Appl Pharmacol 
2005;209:39-50. 
21. Gressier B, Lebegue S, Brunet C, Luyckx M, Dine T, Cazin M, 
et al. Pro-oxidant properties of methotrexate: evaluation 
and prevention by an antioxidant drug. Pharmazie 
1994;49:679-81. 
22. Dinkova-Kostova AT. Protection against cancer by plant phenyl 
propenoids: induction of mammalian anticarcinogenic 
enzymes. Mini Rev Med Chem 2002;2:595-610. 
23. Okado-Mastumoto A, Fridovich I. Subcellular distribution of 
superoxide dismutase (SOD) in rat liver: Cu, Zn-SOD in 
mitochondria. J Biol Chem 2001;276:383-93. 
24. Jwied AH. Hepatoprotective effect of the aqueous extract of 
camellia sinensis against methotrexate-induced liver damage in 
rats. Iraqi J Pharm Sci 2009;18:73-9. 
25. Herman S, Zurgil N, Deutsch M. Low dose methotrexate induces 
apoptosis with reactive oxygen species involvement in T 
lymphocytic cell lines to a greater extent than in monocytic 
lines. Inflammation Res 2005;54:273-80. 
 
